Advertisement

Topics

Mylan $465M Settlement with DOJ Over EpiPen Medicaid Issue Finalized

06:15 EDT 18 Aug 2017 | PharmPro

Mylan finalizes settlement agreement on Medicaid rebate classification for EpiPen Auto-Injector. The question was whether the EpiPen products were properly classified as a non-innovator drug.
Contributed Author: 
Mylan N.V.
Topics: 

Original Article: Mylan $465M Settlement with DOJ Over EpiPen Medicaid Issue Finalized

NEXT ARTICLE

More From BioPortfolio on "Mylan $465M Settlement with DOJ Over EpiPen Medicaid Issue Finalized"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...